August J. Troendle Sells 5,695 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDPGet Free Report) CEO August J. Troendle sold 5,695 shares of Medpace stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $395.49, for a total value of $2,252,315.55. Following the sale, the chief executive officer now directly owns 654,656 shares of the company’s stock, valued at approximately $258,909,901.44. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Medpace Stock Down 0.6 %

Shares of Medpace stock opened at $385.70 on Friday. Medpace Holdings, Inc. has a twelve month low of $202.02 and a twelve month high of $421.00. The business has a 50-day moving average price of $394.56 and a 200 day moving average price of $348.82. The firm has a market cap of $11.95 billion, a PE ratio of 39.32, a P/E/G ratio of 1.93 and a beta of 1.40.

Medpace (NASDAQ:MEDPGet Free Report) last announced its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, beating the consensus estimate of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The firm had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. During the same quarter in the previous year, the business earned $2.27 EPS. Medpace’s revenue for the quarter was up 17.7% compared to the same quarter last year. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 11.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. TD Cowen assumed coverage on Medpace in a report on Wednesday. They issued a “buy” rating and a $452.00 price objective for the company. Robert W. Baird boosted their price objective on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Mizuho assumed coverage on Medpace in a report on Tuesday. They issued a “buy” rating and a $435.00 price objective for the company. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd. Finally, Guggenheim boosted their price objective on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $443.14.

Check Out Our Latest Report on MEDP

Institutional Investors Weigh In On Medpace

Large investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Medpace by 2.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,897 shares of the company’s stock worth $2,114,000 after buying an additional 148 shares in the last quarter. Portside Wealth Group LLC increased its stake in Medpace by 14.8% during the 4th quarter. Portside Wealth Group LLC now owns 1,419 shares of the company’s stock worth $435,000 after buying an additional 183 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Medpace by 355.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company’s stock worth $1,090,000 after purchasing an additional 2,774 shares during the last quarter. Norden Group LLC boosted its holdings in shares of Medpace by 207.8% during the 4th quarter. Norden Group LLC now owns 5,014 shares of the company’s stock worth $1,537,000 after purchasing an additional 3,385 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Medpace during the 4th quarter worth approximately $59,163,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

About Medpace

(Get Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Featured Stories

Insider Buying and Selling by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.